Business Wire

CA-JUNIPER-NETWORKS

23.1.2023 09:01:52 CET | Business Wire | Press release

Share
Juniper Networks Chosen to Upgrade Virgin Media O2’s Core IP Backbone Network to 800G Readiness

Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Virgin Media O2, one of the UK’s largest fixed and mobile service providers with approximately 50 million online media connections, successfully upgraded its IP core backbone network with Juniper – capable of supporting 800G. Virgin Media O2 is investing in sustainable infrastructure for the long term that can support sustained data growth and bandwidth demands. Its investment underpins the rapid introduction of revenue-generating services while delivering significantly-reduced power, cooling and space consumption and costs.

Consistently good user experience is a fundamental benchmark of success. As its 5G and network expansion continues, Virgin Media O2 turned to Juniper to build a network that is 400G-enabled and 800G-ready to create a near future-proofed digital foundation for its customers. Virgin Media O2 selected Juniper as the technology partner for this strategic upgrade for numerous reasons, including its previous track record as a key networking provider for more than ten years with Virgin Media and O2 before their joint venture in 2021. Another significant factor was Juniper’s ability to deliver compelling economics for Virgin Media O2. These include long-term investment protection through continuous custom silicon innovation by keeping pace with market demands, the planned use of automation tools to help reduce operational costs and a favorable Total Cost of Ownership (TCO) with a reduced energy consumption design.

News Highlights

  • In the past year, Virgin Media O2 has seen 32 percent traffic growth on its mobile network, 16 percent growth in broadband data downloads and a peak traffic load of 22TB, underlining the need for increased data capacity and flexible scalability
  • Virgin Media O2 has successfully migrated all core traffic in its six backbone locations across the UK with Juniper Networks PTX10008 Packet Transport Routers, which are purpose-built to deliver cloud-optimized network transformation at scale and with operational flexibility
  • The modular PTX10008 routers deliver reduced resource consumption as a result of inherently-sustainable design features, including front-to-back cooling, flexible power supplies that can use either high- or low-power modes and high-density port capability that enables optimized throughput in a compact form factor
  • Scalable, secure 400G capability is achieved through ultra-high port density, native inline MACSec encryption on all ports, coupled with the latest generation of ASIC innovation that powers a range of line cards
  • PTX10008 routers support 400G coherent optical transceivers (400G ZR and ZR+) without any density loss today, and are 800G-capable with upgradeability to 800G in the future with silicon innovation and easily-exchanged line cards in the chassis
  • Virgin Media O2’s infrastructure will be underpinned by Juniper’s single operating system, Junos® OS Evolved. This will provide ongoing continuity for streamlined operations.

Supporting Quotes

“Virgin Media O2’s stated ambition is to ‘upgrade the UK’, providing fast, seamless broadband access and mobile services to as many homes and businesses as possible. This calls for responsible, strategic innovation and investment to create an agile network infrastructure that can simultaneously scale in step with our business, be mindful of resource consumption and deliver an extended lifecycle that protects our investment. Juniper is a long-standing technology partner, so it is very reassuring that it has the same vision for sustainable growth, user experience and the fundamental importance of digital enablement in our communities and economy.”

- Jeanie York, Chief Technology Officer, Virgin Media O2

“Service providers face a complex set of technical and commercial challenges that can be contradictory, even intractable—and likely only to multiply in the future—without the right approach. Virgin Media O2 has chosen to leverage silicon, software and automation innovation from Juniper that can turn complexity on its head to deliver a simplified, more reliable and more sustainable network foundation for its business. This means the company can embrace and accelerate growth and service evolution, safe in the knowledge that its millions of users will continue to be able to enjoy the best digital experiences going forward, whatever demands the future may bring.”

- Raj Yavatkar, Chief Technology Officer, Juniper Networks

Additional Information

Juniper’s Climate Change & Sustainability Pages
CEO Blog: Juniper’s Carbon Neutral Pledge
CTO Blog: Sustainable Networking – The Time is Now
Juniper’s 2022 Corporate Sustainability Report

About Juniper Networks

Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

Statement of Product Direction

The information on this page may contain Juniper's development and plans for future products, features, or enhancements ("SOPD Information"). SOPD Information is subject to change at any time, without notice. Juniper provides no assurances, and assumes no responsibility, that future products, features, or enhancements will be introduced. In no event should any purchase decision be based upon reliance of timeframes or specifics outlined as part of SOPD Information, because Juniper may delay or never introduce the future products, features, or enhancements.

Any SOPD Information within, or referenced or obtained from, this website by any person does not give rise to any reliance claim, or any estoppel, against Juniper in connection with, or arising out of, any representations set forth in the SOPD Information. Juniper is not liable for any loss or damage (howsoever incurred) by any person in connection with, or arising out of, any representations set forth in the SOPD Information.

Category - Cloud & Service Provider

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005101/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye